Introduction {#Sec1}
============

The β-adrenoceptor (β-AR), a member of the G-protein-coupled receptor (GPCR) family, has been the object of several studies aimed at understanding its physiological role and establishing structure--activity relationships for ligands which bind selectively to specific subtypes (Bikker *et al*., [@CR6]; Lefkowitz, [@CR30]; Wess, [@CR56]; Schoneberg *et al*., [@CR44]). β-ARs are widely distributed in the human body and are found, for example, in the lung, heart, and adipose tissue. The β-AR subtypes mediate several physiological processes including heart rate (Baker, [@CR4]) (β-1), bronchodilatation (Waldeck, [@CR51]; Sears, [@CR45]) (β-2), and lipolysis (Weyer et al*.*, [@CR53]) (β-3). The β~3~-AR is involved in various pharmacological and physiological effects including lipolysis, thermogenesis, and relaxation of intestinal smooth muscle (deSouza and Burkey, [@CR11]; Dow, [@CR12]; Igawa *et al.*, [@CR24]). Agents which selectively activate β~3~-ARs were proposed to be useful in the treatment of obesity (Weyer *et al.*, [@CR57]), non-insulin-dependent diabetes mellitus, and frequent urination. β~3~-AR agonists stimulate the intracellular signaling process to initiate the lipolysis of triglycerides in white adipose tissue. The resulting free fatty acids are processed by uncoupling protein, leading to thermogenesis in brown adipose tissue. The glucose-lowering effect of β~3~-AR agonists is mediated through improved peripheral insulin sensitivity. The exact mechanism of the antidiabetic action of this class of compounds is not fully understood. Most of the previously developed β~3~-AR compounds have suffered from one or more unacceptable pharmacokinetic or pharmacodynamic problems, including lack of β~3~-AR selectivity, tissue specificity, full agonist activity, drug toxicity, and a short plasma half-life (Arch and Wilson, [@CR1]; Himms-Hagen and Danforth, [@CR19]; Danforth and Himms-Hagen, [@CR10]), as a result of which no drug targeted to human the β~3~-AR has reached the market so far. Hence attempts to identify clues for β~3~-AR selectivity are an urgent requirement.

Many structural classes of β~3~-adrenoceptor agonists have been developed; prominent among these classes are the derivatives of arylethanolamine and aryloxypropanolamine (Kordik and Reitz, [@CR28]). The following are the important leads in these series: BRL-37344 (Arch *et al.*, [@CR2]), CL-316243 (Bloom *et al.*, [@CR7]), BMS-201620 (Washburn *et al.*, [@CR54]), and L-749372 (Naylor *et al.*, [@CR35]). BRL-37344 was reported to be a selective β~3~-AR partial agonist (β~3~ EC~50~ = 450 nM, 23% activation) (Naylor *et al.*, [@CR35]). L-749372 is also a β~3~-AR partial agonist (EC~50~ = 3.6 nM, 33% activation), with 270- and 30-fold selectivity over binding to β~1~- and β~2~-ARs, respectively (Naylor *et al.*, [@CR35]). The 4-piperidino-benzoic acid derivative CL-316243 was found to be a modestly potent human β~3~-AR agonist (EC~50~ = 0.22 μM) (Sum *et al.*, [@CR48]), and *N*-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamide (BMS-201620) a potent β~3~ full agonist (*k*~*i*~ = 93 nM) (Washburn *et al.*, [@CR54]).

A schematic diagram showing the important structural units considered for β~3~-AR agonistic activity in recently reported molecules is given in Scheme [1](#Sch1){ref-type="fig"}. The chirality at the hydroxyl center shows that (R) isomers possess the most favorable β~3~ potency and selectivity profile over (S) isomers (Washburn *et al.*, [@CR53]). The aryl group attached to the ethanolamine substructure is important for the biological activity, which can be either phenyl (Nakajima *et al.*, [@CR34]), pyridine (Naylor *et al.*, [@CR36]; Parmee *et al.*, [@CR40]), *N*-(2-hydroxy-phenyl)methanesulfonamide (Gavai *et al.*, [@CR16]; Hu *et al.*, [@CR22]) or phenol (Parmee *et al.*, [@CR39]; Weber *et al.*, [@CR55]). β~3~-AR agonist activity of 2,4-thiazolidinedione with several β-amino alcohols (R1) was reported by Hu *et al.* ([@CR21]). The amine portion of the ethanolamine group was attached to the central aryl fragment by a two- or three-carbon atom spacer. The central aryl linker fragment was replaced by a benzene (Naylor *et al.*, [@CR35]) or indole moiety (Harada *et al.*, [@CR18]). The central aromatic region was linked to the sulfonamide group, which is understood to be essential for selectivity of β~3~-AR agonistic activity (Uehling *et al.*, [@CR49]). Various research groups introduced acidic functionality on R2 to increase the selectivity for β~3~-AR activity. In addition, they suggested that the steric bulk of the R2 substituent also contributed to the potency and selectivity of β~3~-AR agonists. However, it is thought that introduction of such hydrophilic groups may generally cause low oral bioavailability, partly due to poor absorption (van de Waterbeemd *et al.*, [@CR50]). Numbers of various bulky fragments attached to R2 have been reported. These fragments are long chains with oxadiazolidinedione (Hu *et al.*, [@CR23]), thiazolidinediones (Hu *et al.*, [@CR20]), urea (Ashwell *et al.*, [@CR3]), triazole (Brockunier *et al.*, [@CR8]), oxazole (Ok *et al.*, [@CR37]), oxadiazole (Feng *et al.*, [@CR13]; Biftu *et al.*, [@CR5]), thiazole (Mathvink *et al.*, [@CR31]), etc.Scheme 1Essential pharmacophore elements present in β~3~-AR agonists, as identified from the reported β~3~-selective arylethonolamine/aryloxypropanolamine derivatives

Molecular modeling studies offer several valuable tools for understanding the interactions of drugs and their receptors on a molecular level (Silverman, [@CR46]). In the case of β-ARs very few molecular modeling studies have appeared to date. This is mainly due to the absence of three-dimensional (3D) information about these receptors. Some bold attempts have been made to computationally model the 3D structure of these targets. Lybrand *et al.* reported 3D models for agonist and antagonist complexes with β-adrenoceptors using computer modeling techniques (Kontoyianni *et al.*, [@CR27]; Furse and Lybrand, [@CR14]). Saxena and coworkers reported 3D quantitative structure--activity relationship (QSAR) studies on a cyclic ureidobenzenesulfonamides series of molecules using the Apex-3D method (Kashaw *et al.*, [@CR26]; Prathipati and Saxena, [@CR41]), and comparative molecular field analysis (CoMFA) and CoMSIA for different therapeutic areas (Gyanendra *et al.*, [@CR17]; Stuti *et al.*, [@CR47]). Recently, we reported CoMFA studies on a 4-aminomethylpiperidine series of β~3~-AR agonists (Kumar and Bharatam, [@CR29]). In this paper we report comparative studies on the molecular field requirements for a tryptamine based series of molecules toward β~1~-, β~2~-, and β~3~-ARs. Kato and coworkers reported the relative biological activities of tryptamine-based agonists toward β~1~-, β~2~-, and β~3~-ARs and pointed out that the compounds may be more specific to β~3~-ARs (Mizuno *et al.*, [@CR32], [@CR33]; Sawa *et al.*, [@CR42], [@CR43]). A set of 27 molecules from these series was employed in this work to carry out CoMFA studies to identify relative steric and electronic requirements against these three receptors.

Computational details {#Sec2}
---------------------

All molecular modeling techniques and CoMFA studies were performed on a Silicon Graphics Octane2 (R12000) workstation with an IRIX6.5 operating system using the sybyl6.9 molecular modeling software package from Tripos, Inc. (St. Louis, MO, USA, 2002).

Data sets {#Sec3}
---------

CoMFA was performed on a series of 27 tryptamine derivatives for which biological activities (EC~50~ values) are reported with respect to β~1~-, β~2~-, and β~3~-ARs (Harada *et al.*, [@CR18]; Mizuno *et al.*, [@CR32], [@CR33]; Sawa *et al.*, [@CR42], [@CR43]). The structures and biological activity values of the 27 compounds forming the training set and test set are listed in Table [1](#Tab1){ref-type="table"}; they were assayed in one research laboratory under the same experimental conditions. Only those compounds for which all three biological activities toward β-ARs were available (i.e., β~1~, β~2~, and β~3~) were selected from the published data. The EC~50~ is the concentration at which half the maximal response of the compound was observed. Biological activities are reported with EC~50~ values ranging from 0.13 to 1700, 5.2 to 330, and 0.062 to 220 nM for human β~1~-, β~2~-, and β~3~-ARs, respectively. The biological activities in the training set were converted to pEC~50~ values of the agonists, which are the negative logarithms of the molar concentration value, and used as dependent variables in the CoMFA.Table 1Structures of the 27 agonists in the training set and test set and their reported biological activity values ![](44_2009_9257_Figb_HTML.gif){#d28e751}MoleculeSubstituent Rβ~1~-AR EC~50~ (nM)β~2~-AR EC~50~ (nM)β~3~-AR EC~50~ (nM)**1**^a^--1.9255.4**2**^b^--47330220**3**Me0.135.20.36**4**CH~2~COOH6.4130.062**5**--170029021.0**6**H21660.88**7**OMe6.6290.55**8**OCH~2~Ph6.6540.76**9**OCH~2~CONEt~2~6.8191.30**10**OCH~2~COOH191801.70**11**OSO~2~Me18440.21**12**OSO~2~-*n*-butyl7.3260.59**13**OSO~2~-*n*-octyl5.6200.28**14**OSO~2~-iPr6.2400.51**15**OSO~2~Ph3.1720.87**16**OSO~2~-3-pyridyl1.3220.26**17**OSO~2~-2-thienyl1.2490.64**18**OSO~2~-2-CO~2~Et7.2581.20**19**--13260.47**20**--19130.54**21**--69120160**22**![](44_2009_9257_Figc_HTML.gif){#d28e1211}101701.2**23**![](44_2009_9257_Figd_HTML.gif){#d28e1230}3616036**24**![](44_2009_9257_Fige_HTML.gif){#d28e1248}9.64510**25**![](44_2009_9257_Figf_HTML.gif){#d28e1266}7.6442.9**26**--22324.4**27**--44531.0^a^Configuration R at hydroxyl and methyl center^b^Configuration S at hydroxyl and R at methyl center

Structure generation and alignment {#Sec4}
----------------------------------

Compounds in the training set were generated from the x-ray crystal structures or by modification of the crystal structure of similar compounds using the SYBYL BUILD option (Tripos Inc. [@CR25]). Conformation of compound **4** in the training set was taken from the x-ray crystal structure reported on the same molecule as given in the Cambridge Crystallographic Structural Database Centre (CCDC No. 203813) (Harada *et al.*, [@CR18]). All remaining compounds were built from the crystal structure of compound **4**. Energy minimization was performed using the Tripos force field with a distance-dependent dielectric and conjugate gradient algorithm with a convergence criterion of 0.005 kcal/mol. Partial atomic charges were calculated using the Gasteiger--Huckel method (Gasteiger and Marsili, [@CR15]). CoMFA studies require that the 3D structures of the molecules to be analyzed be aligned according to a suitable conformational template, which is assumed to be a "bioactive" conformation. Molecular alignment was carried out using the SYBYL "fit-atom" alignment function (Tripos Inc. [@CR25]). The crystal structure of compound **4** was used as the alignment template. Figure [1](#Fig1){ref-type="fig"} shows the 3D alignment of 27 molecules according to the alignment scheme in Fig. [2](#Fig2){ref-type="fig"}.Fig. 1The 3D alignment of the 27 molecules is shown by capped sticks without hydrogensFig. 2Molecule **4** with atoms used for superimposition are named 1 to 7

CoMFA study {#Sec5}
-----------

The CoMFA descriptors were used as independent variables, and pEC~50~ values where used as dependent variables, in partial least squares (PLS) (Wold *et al.*, [@CR58]) regression analysis to derive 3D QSAR models. The steric (Lennard-Jones) and electrostatic (Coulomb) CoMFA fields were calculated using an *sp*^3^ carbon as the steric probe atom and a +1 charge for the electrostatic probe. A grid spacing of 2 Å and a distance-dependent dielectric constant were chosen. The cutoff value for both steric and electrostatic interactions was set to 30 kcal/mol.

Partial least squares analysis {#Sec6}
------------------------------

PLS regression analyses were performed using cross-validation to evaluate the predictive ability of the CoMFA models. Initial PLS regression analyses were performed in conjunction with the cross-validation (leave-one-out method) option to obtain the optimal number of components to be used in the subsequent analysis of the dataset. All the leave-one-out cross-validated PLS analyses were performed with a column filter value of 2.0 kcal/mol to improve the signal-to-noise ratio by omitting those lattice points whose energy variation was below this threshold value. The final PLS regression analysis with 10 bootstrap groups and the optimal number of components was performed on the complete dataset. The optimal number of components was determined by selecting the smallest PRESS value. Usually this value corresponds to the highest cross-validated $\documentclass[12pt]{minimal}
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Test sets {#Sec7}
---------

To test the predictive power of the CoMFA model, seven agonists from the β~1~- and β~2~-AR subtypes and five agonists from the β~3~-AR subtype were selected as the test set (Table [2](#Tab2){ref-type="table"}). The agonists in the test set were chosen by random sampling of biological activity. The conformation, minimization, and alignment of these agonists in the test set were obtained by the same protocol as that described for the agonists in the training set used. All predicted activities for test-set molecules were calculated using the optimized CoMFA model. The results of the non-cross-validated calibration model on the test sets are summarized in Table [3](#Tab3){ref-type="table"}.Table 2Experimental (exp) and predicted (pre) biological activities along with estimated residual values (res) of training- and test-set molecules (log 1/EC~50~) × 10^−9^ associated with the three CoMFA models β~1~, β~2~, and β~3~Moleculeβ~1~β~2~β~3~ExpPreResExpPreResExpPreRes**1**8.727.661.067.606.381.228.266.991.27**2**7.327.260.066.486.420.066.656.610.04**3**9.887.692.198.286.641.649.446.912.53**4**8.198.170.027.886.591.2910.207.272.93**5**5.767.76--2.06.536.59--0.067.677.28--0.01**6**7.677.68--0.017.187.20--0.029.059.12--0.07**7**8.188.180.007.537.440.099.259.210.04**8**8.188.24--0.067.267.29--0.039.119.060.05**9**8.168.69--0.537.727.76--0.048.888.93--0.05**10**7.727.90--0.186.747.33--0.598.768.700.06**11**7.748.05--0.317.357.36--0.019.679.590.08**12**8.138.19--0.067.587.370.219.229.24--0.02**13**8.258.180.077.697.690.09.559.530.02**14**8.208.26--0.067.397.420.039.299.33--0.04**15**8.508.64--0.147.147.24--0.109.069.15--0.09**16**8.888.870.017.657.240.419.589.390.19**17**8.928.880.047.307.31--0.019.199.21--0.02**18**8.148.39--0.257.237.200.038.928.95--0.03**19**7.887.820.067.587.66--0.089.329.34--0.02**20**7.727.710.017.887.730.159.269.190.07**21**7.167.19--0.036.927.70--0.786.799.19--2.4**22**8.008.03--0.036.766.79--0.038.927.671.25**23**8.008.08--0.086.796.720.077.447.410.03**24**8.017.160.857.347.340.08.008.000.0**25**8.118.110.007.357.36--0.018.538.54--0.01**26**7.657.66--0.017.497.50--0.018.358.38--0.03**27**7.357.36--0.017.297.34--0.059.009.07--0.07*Note*: β~1~-AR: training set, **2**, **4**, **6--8**, **12--14**, **16**, **17**, **19--22**, **25--27**; test set, **9--11**, **15**, **18**, **23**, **24**; outliers, **1**, **3**, **5**. β~2~-AR: training set, **2**, **5--9**, **11**, **13**, **15**, **18--20**, **22--26**; test set, **10**, **12**, **14**, **16**, **17**, **21**, **27**; outliers, **1**, **3**, **4**. β~3~-AR: training set, **2**, **5--7**, **9**, **11--13**, **15--17**, **19**, **23--27**; test set, **8**, **10**, **14**, **18**, **20**; outliers, **1**, **3,4**, **21**, **22**Table 3Statistical parameters associated with the three CoMFA models β~1,~ β~2~, and β~3~Parameterβ~1~β~2~β~3~*N*171717No. components556$\documentclass[12pt]{minimal}
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Predictive *r*^2^ values {#Sec8}
------------------------
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                \begin{document}$$ r^{ 2}_{\text{pre}} = \left({{\text{SD}}-{\text{PRESS}}} \right)/{\text{SD}} $$\end{document}$$where SD is the sum of the squared deviations between the biological activities of molecules in the test set and the mean activity of the training-set molecules, and PRESS is the sum of the squared deviations between predicted and actual biological activity values for every molecule in the test set. This is analogous to Cramer's definition: whenever PRESS is larger than SD, this results in a negative value reflecting complete lack of predictive ability of the training set for the molecules included in the test set (Cramer *et al.*, [@CR9]).

Results {#Sec9}
=======

CoMFA of the β~1~-adrenoceptor {#Sec10}
------------------------------

PLS analysis was used in combination with cross-validation to obtain the optimal number of components to be used in the subsequent non-cross-validation analysis. PLS analysis based on least squares fit gave a correlation with a cross-validated $\documentclass[12pt]{minimal}
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                \begin{document}$$ r^{2}_{\text{ncv}} $$\end{document}$ of 0.993. To obtain statistical confidence limits, the non-cross-validated analysis was repeated with 10 bootstrap groups, which yielded an *r*^2^ of 0.996 (five components, SEE = 0.027, std dev = 0.003, steric contribution = 0.558, and electrostatic contribution = 0.442). These parameters are listed in Table [3](#Tab3){ref-type="table"}. The above satisfactory cross-validated correlation coefficient indicates that the CoMFA model is highly reliable. The high bootstrapped *r*^2^ value and low standard deviation suggest a high degree of confidence in the analysis. The calculated biological activities obtained from the analysis are plotted versus the actual values in Fig. [3](#Fig3){ref-type="fig"}a. Compounds **9**, **10**, **11**, **15**, **18**, **23**, and **24** (test set) were used to evaluate the predictive power of this CoMFA model. As in the calibration step, a good predictive ability, with an $\documentclass[12pt]{minimal}
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                \begin{document}$$ r^{2}_{\text{pre}} = 0. 8 4 7 $$\end{document}$, for the compounds in the test set was obtained. Table [2](#Tab2){ref-type="table"} reports that the predicted values fall close to the observed biological activity value, deviating by less than one logarithmic unit.Fig. 3A graph of experimental vs. predicted activities of the training-set and test-set molecules as β~1~-AR (**a**), β~2~-AR (**b**), and β~3~-AR (**c**) agonists. (![](44_2009_9257_Figg_HTML.gif){#d28e2990}) Training set; (![](44_2009_9257_Figh_HTML.gif){#d28e2993}) test set

The β~1~ CoMFA steric and electrostatic fields from the final non-cross-validated analysis are plotted as three-dimensional color contour maps in Figs. [4](#Fig4){ref-type="fig"}a and [5](#Fig5){ref-type="fig"}a, respectively, along with the reference compound, **16**. These contour maps indicate the regions where differences in molecular fields are associated with differences in biological activity. Green contours indicate regions in which increasing steric bulk is tolerable, and yellow contours indicate regions in which the steric bulk decreases the activity. In the β~1~ model the steric contours show that the substituents attached to the ring of the arylethanolamine group are placed in sterically unfavorable regions. Of the four yellow contours near the arylethanolamine group three of them are below the local plane of the reference compound and one is above the five-membered ring of the reference compound. These yellow regions indicate that additional steric interactions in these regions would lead to decreased biological activity. The above observations indicate that for good β~1~-agonistic activity there should be only very small groups or no substituents on the aryl ring of arylethanolamine. These can account for a limiting size and shape for the substituents that would be effective for tight binding to the receptor. A big yellow contour above the indole ring indicates that any substituents on the nitrogen of the indole ring would greatly reduce the biological activity, suggesting limited bulk tolerance. The small green region at the C7 position of the indole nucleus indicates that increases in the steric bulk at this position are marginally favorable for β~1~-AR activity. The electrostatic contour map (Fig. [5](#Fig5){ref-type="fig"}a) of the CoMFA model shows a small blue contour near the SO~2~ group attached to arylethanolamine and red contours near the C7 substituents on the indole ring. This indicates that a reduction in the electronegativity near the SO~2~ group and increasing electronegativity at the C7 position of indole should lead to increased β~1~ activity.Fig. 4CoMFA steric STDEV\*COEFF contour plots of the tryptamine-based derivative training set generated for the β~1~ (**a**), β~2~ (**b**), and β~3~ (**c**) models. Compounds **16** (**a**, **c**) and **20** (**b**) are shown inside the fieldFig. 5CoMFA electrostatic STDEV\*COEFF contour plots of the tryptamine-based derivative training set generated for the β~1~ (**a**), β~2~ (**b**), and β~3~ (**c**) models. Compounds **16** (**a**, **c**) and **20** (**b**) are shown inside the field

CoMFA of the β~2~-adrenoceptor {#Sec11}
------------------------------

The β~2~ CoMFA analysis based on the fit atom alignment yielded good cross-validated ($\documentclass[12pt]{minimal}
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                \begin{document}$$ r^{2}_{\text{bs}} $$\end{document}$ value of 0.997 (SEE = 0.023, std dev = 0.003) was found. A plot of actual versus calculated biological activity obtained from the analysis is given in Fig. [3](#Fig3){ref-type="fig"}b. Compounds **10**, **12**, **14**, **16**, **17**, **21**, and **27** (test set) were used to evaluate the predictive power of this CoMFA model. A good predictive ability, with an $\documentclass[12pt]{minimal}
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The β~2~ CoMFA steric and electrostatic fields from the final non-cross-validated analysis are plotted in Figs. [4](#Fig4){ref-type="fig"}b and [5](#Fig5){ref-type="fig"}b respectively. The most active compound, **20**, was treated as the reference molecule. The graphical interpretation of the field contribution of the steric contour map is shown in Fig. [4](#Fig4){ref-type="fig"}b. The steric contour map shows three yellow regions surrounding the phenyl unit in the NHSO~2~Ph group, and a small green at the para position on the same ring. This indicates that it is preferable to reduce the steric bulk due to the Ph group. The presence of a simple thiophen ring, as in many other molecules in this series, is preferable for β~2~ activity. A very large yellow contour is noted near the C7 of the indole ring in Fig. [4](#Fig4){ref-type="fig"}b, indicating that the steric bulk should be reduced for improved β~2~ activity. The CoMFA electrostatic contour map displays a large blue region surrounding the SO~2~Ph group and two small red regions in close proximity, suggesting that a strong reduction in the electronegative groups is preferred in this region. There are two small blue regions and one small red region at the C7 of the indole ring of the reference compound. The distribution range of blue is higher than that of red, indicating that electropositive groups in this region are very important for the β~2~ biological activity.

CoMFA of the β~3~-adrenoceptor {#Sec12}
------------------------------

The β~3~ CoMFA analysis based on the fit atom alignment yielded acceptable cross-validated ($\documentclass[12pt]{minimal}
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The steric and electrostatic contour maps obtained from the β~3~ CoMFA model are shown in Figs. [4](#Fig4){ref-type="fig"}c and [5](#Fig5){ref-type="fig"}c, respectively, along with compound **16**. In Fig. [4](#Fig4){ref-type="fig"}c, the steric contour map shows a large green region around the substituent on the aryl ring, indicating the presence of a β~3~-AR binding pocket which can accommodate bulky substituents of large size, such as isopropyl and t-butyl. The presence of a bulky substituent at the indole ring decreases activity because of steric hindrance, as indicated by the yellow contour. Figure [5](#Fig5){ref-type="fig"}c shows a huge blue contour near the thiophen ring, indicating that decreasing electronegative character/increasing electropositive character is an important consideration in this region for improved β~3~-agonistic activity.

Discussion {#Sec13}
==========

Three different 3D QSAR models have been developed using the CoMFA methodology for tryptamine-based analogues of β-AR agonists. This is a first attempt to describe quantitatively the hypothetical receptor binding site of multiple subtypes of β-ARs. Comparison of the three CoMFA models helps in understanding β-AR selectivity. The main steric and electrostatic interactions on the binding cavity of β~1~-, β~2~-, and β~3~-ARs are demonstrated in Scheme [2](#Sch2){ref-type="fig"}. The 3D QSAR CoMFA of these β-AR subtypes led to the following considerations:Scheme 2Proposed hypothetical receptor model of β-Ars binding site

The β~2~ and β~3~ CoMFA models show similarities in their overall steric and electrostatic contributions. In the β~1~ CoMFA model the steric contribution is larger, whereas in the β~2~ and β~3~ CoMFA models the electrostatic contribution is larger (see Table [3](#Tab3){ref-type="table"}). Detailed CoMFA contour map analysis shows that decreasing steric bulk is preferable for increased β~1~ and β~2~ activity near the sulfonamide unit. On the other hand, increasing steric bulk is preferable for the β~3~-AR activity near the phenyl sulfonamide unit. Strong yellow contours are observed near the C7 unit of the indole ring in all three CoMFA models, indicating that smaller functional units are preferable in this region. From this information, it may be inferred that the active site of β~3~-AR can accommodate large substituents on the left-hand side for tight binding. Thus, β~3~-selectivity of this series of compounds can be brought about by employing large groups on the phenyl unit of phenyl sulfonamide in **16**. It is preferable to reduce the steric effects on the C7 of the indole ring in **16** for all (β~1~, β~2~, β~3~) activities. Figure [5](#Fig5){ref-type="fig"} shows that there are distinguishable differences in the electrostatic fields of β~1~, β~2~, and β~3~ CoMFA models. In all the models, increasing electropositive character is preferred near the SO~2~Ar unit in **16**, the influence of which increased in the order β~1~ \< β~2~ \< β~3~. This requirement is very strong for β3-agonistic activity. Thus, large substituents with a strong electropositive character on the Ar unit of SO~2~Ar are required for β~3~ specificity. On the other hand, electrostatic factors appear to be optimum for β~3~ activity on the right-hand side of Scheme [2](#Sch2){ref-type="fig"}. However, increasing electronegative substituents are favorable for β~1~ activity and increasing electropositive character is favorable for β~2~ selectivity. These factors are summarized in Scheme [2](#Sch2){ref-type="fig"}. In summary, the absence of information on the experimental binding mode of these agonists toward their β-ARs, the binding mode information obtained for the comparative 3D QSAR studies shall be helpful in modulating the tryptamine series of molecules for selectivity against β~1~, β~2~, and β~3~ activities.

Conclusion {#Sec14}
==========

In this paper, we have established CoMFA models for a series of tryptamine-based analogues for various subtypes of β-AR agonists, i.e., β~1~-, β~2~-, and β~3~-AR agonists. Three different 3D QSAR models have been established for β~1~-AR, β~2~-AR, and β~3~-AR agonistic activities in a series of tryptamine molecules using the CoMFA method. All three models show satisfactory statistical significance values $\documentclass[12pt]{minimal}
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                \begin{document}$$ r^{ 2}_{\text{cv}} $$\end{document}$ (0.578, 0.575, 0.558), SEE (0.027, 0.023, 0.033), etc. Comparative study of the steric and electrostatic contour maps provided clues to the chemical modulations required for improving specificity. For β~3~-specificity, for example, increased steric bulk and increased electropositive character are required on the aryl group of the SO~2~Ar unit in this series of molecules. Based on the present 3D QSAR CoMFA studies, a hypothetical receptor model of these agonists with the β~3~-AR is proposed (see Scheme [2](#Sch2){ref-type="fig"}). Since information related to the 3D structure of the active site of the three β-ARs is not available, information provided in this article in the form of molecular field requirement shall be of help in designing selective β~3~-AR agonists.
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